References
ADVERSE EVENTS
Flowchart of study visits.Flowchart of participants.Time-course of plasma carotenoid concentrations. Mean plasma carotenoid concentrations in (µmol/L) ± standard error of the mean are shown at weeks 0, 2, 4, and 8. The placebo group is represented with blue lines, the 3 mg β-cryptoxanthin group is represented with red lines, and the 6 mg β-cryptoxanthin group is represented with green lines. (Fold changes of retinol-dependent gene expression in peripheral blood mononuclear cells from placebo and β-cryptoxanthin supplementation groups. Fold changes in gene expression from baseline to week 8 were calculated using normalized Cq values. Values are expressed as mean ± standard deviation. Dose of β-cryptoxanthin in mg per day is indicated on the Alpha diversity of the gut microbial community in 3 different treatment groups before and after supplementation. (Beta diversity of the gut microbial community in 3 different treatment groups before and after supplementation. Principal coordinate analysis based on (Baseline study demographics and carotenoid intake and plasma concentrations.Data are presented as median (interquartile range) or mean ± standard deviation unless otherwise indicated. Summary of reported adverse events.Vital signs and laboratory parameters at baseline and after 8 weeks supplementation.Data are presented as median (interquartile range) or mean ± standard deviation unless otherwise indicated. Mood, physical activity, and sleep at baseline and after 8 weeks supplementation.Data are presented as median (interquartile range) or mean ± standard deviation unless otherwise indicated. 